ArticlePloS one2014
MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis.Disease markers · 2015Pooled it
- Bioinformatics Analysis of microRNAs Associated with Metastatic Potential in Breast Cancer.Biology · 2026Article
- MicroRNA-155 as Biomarker and Its Diagnostic Value in Breast Cancer: A Systematic Review.World journal of oncology · 2025Review
- Dynamic Role of miRNAs in Salivary Gland Carcinomas: From Biomarkers to Therapeutic Targets.Head and neck pathology · 2024Review
- Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.BMC cancer · 2022Article
- Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer.Molecular biology reports · 2020Article
- The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics.Molecular therapy. Nucleic acids · 2020Review
- Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer.PloS one · 2020Article
- Prognostic role of microRNAs in breast cancer: A systematic review.Oncotarget · 2019Article
- Review
- OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.Scientific reports · 2018Article
- MicroRNAs in regulation of triple-negative breast cancer progression.Journal of cancer research and clinical oncology · 2018Review
- Levels of MicroRNA Heterogeneity in Cancer Biology.Molecular diagnosis & therapy · 2017Review
- MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer.Oncology letters · 2017Article
- Critical role of HMGA proteins in cancer cell chemoresistance.Journal of molecular medicine (Berlin, Germany) · 2017Review
- MicroRNA in breast cancer: The association with BRCA1/2.Cancer biomarkers : section A of Disease markers · 2017Review
- MicroRNAs in the development and neoplasia of the mammary gland.F1000Research · 2017Review
- Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis.Oncotarget · 2016Review
- Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMicroRNAs are small, non coding regulatory molecules containing approximately 21 to 25 nucleotides. They function as controllers of expression at post transcriptional levels of most human protein-coding genes and play an essential role in cell signaling pathways. The objective of the present study is to evaluate the expression profile of the following micro-RNAs: miR-10b, miR-17, miR-21, miR-34a, miR-146a, miR-148a and miR-182, and to determine their possible interaction in triple-negative and non triple-negative primary breast cancers based on clinical outcome.
methods60 triple-negative and non triple-negative breast cancer cases, along with their corresponding normal samples were investigated in relation to the expression of the seven studied miRNAs using qPCR Syber Green.
resultsWe observed that miR-21, miR-146a and miR-182 were significantly over expressed in triple negative breast cancer. Moreover, miR-10b, miR-21 and miR-182 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma while only miR-10b was associated with grade III in non triple negative breast cancer cases. Almost all the analyzed microRNAs were strongly associated with patients' genico-obstetric history in non triple negative breast cancer cases except for miR-34a. All the studied microRNAs were strongly correlated with the use of the contraceptive pills in non triple negative breast cancer groups. The additive effect of hormonal factors in triple negative breast cancer cases showed an association with all the studied miRs except for miR-34 and miR-146a.
conclusionThe studied microRNAs are strongly influenced by environmental factors especially with hormonal patients' history. Moreover, miR-10b, miR-21 and miR-182 could be defined as biomarkers in breast cancer to predict both lymph node metastases and grade III occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.